BioCentury This Week

Ep. 336 - Cautious Optimism and M&A Momentum


Listen Later

There is cautious optimism around continued M&A momentum and the public equities markets as biotech heads into the New Year. On a special edition of the BioCentury This Week podcast recorded in London during London Life Sciences Week, BioCentury’s Simone Fishburn and Stephen Hansen were joined by a trio of guests to discuss their key takeaways from the week and expectations for next year, including trends in M&A and creative deal structures for business development.
The group also discussed the potential for biotech venture investing to make a comeback as a key asset class for LPs, especially in the U.K., as the government continues to encourage pension funds to invest more broadly.
The three guests joining BioCentury included Luciana Griebel from law firm Morgan Lewis, James Critchley from PJT Partners, and Carmine Circelli from the British Business Bank.
The podcast was recorded Nov. 19 on stage at the Victoria House in London as part of the 3rd Biotech CEO & Investor Reception.
BioCentury’s next recording “on the road” will take place on the sidelines of the annual J.P. Morgan Healthcare Conference in San Francisco in January at the 11th East West Healthcare Reception hosted by BioCentury, Panacea Venture and Maytech Global Investments.

View full story: https://www.biocentury.com/article/657686

#BiotechMandA #DrugDevelopment #VentureCapital #LifeSciences #LondonLifeSciencesWeek

00:00 - Introduction
02:24 - Market Recovery
08:02 - Growth and Influence
16:24 - Creative Dealmaking
21:40 - Role of CVRs
25:52 - Pension Funds and Venture Capital
30:09 - AI Bubble
34:17 - Accelerating Clinical Trials

Morgan Lewis has prepared its materials for this podcast for general informational purposes only. They do not and are not intended to constitute legal advice. This podcast was recorded on Nov. 19. Morgan Lewis does not guarantee the accuracy or timeliness of the information contained in these materials and disclaims any obligation to advise you of any changes in the law. You should always refer to original source documents for complete information and consult directly with an attorney for advice, including on the latest developments in this rapidly changing area of the law.

To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].

Reach us by sending a text

...more
View all episodesView all episodes
Download on the App Store

BioCentury This WeekBy BioCentury

  • 4.8
  • 4.8
  • 4.8
  • 4.8
  • 4.8

4.8

31 ratings


More shows like BioCentury This Week

View all
Exchanges by Goldman Sachs

Exchanges

979 Listeners

WSJ What’s News by The Wall Street Journal

WSJ What’s News

4,366 Listeners

Bloomberg Intelligence by Bloomberg

Bloomberg Intelligence

402 Listeners

Odd Lots by Bloomberg

Odd Lots

1,929 Listeners

Bloomberg Businessweek by Bloomberg

Bloomberg Businessweek

438 Listeners

The Readout Loud by STAT

The Readout Loud

324 Listeners

The Journal. by The Wall Street Journal & Spotify Studios

The Journal.

6,068 Listeners

Biotech 2050 Podcast by Biotech 2050

Biotech 2050 Podcast

61 Listeners

All-In with Chamath, Jason, Sacks & Friedberg by All-In Podcast, LLC

All-In with Chamath, Jason, Sacks & Friedberg

9,957 Listeners

Business Of Biotech by Ben Comer

Business Of Biotech

86 Listeners

Biotech Hangout by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more

Biotech Hangout

19 Listeners

The Markets by Goldman Sachs

The Markets

75 Listeners

Ground Truths by Eric Topol

Ground Truths

48 Listeners

The Top Line by Fierce Life Sciences

The Top Line

14 Listeners

The BioCentury Show by BioCentury

The BioCentury Show

12 Listeners